Status:

UNKNOWN

Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS

Lead Sponsor:

Ain Shams University

Conditions:

Polycystic Ovary Syndrome

Eligibility:

FEMALE

20-35 years

Phase:

NA

Brief Summary

Polycystic ovary syndrome (PCOS) is found in 5% to 6% of women of reproductive age. It affects women's reproductive capability; thus patients have risks of infertility, miscarriage, and complicated pr...

Eligibility Criteria

Inclusion

  • Women diagnosed with PCOS
  • Women 20-35 years old.
  • BMI ≤30 kg/m without previous ovulation induction.
  • Partners with normal semen parameters Parameter World Health Organization (WHO) 2010 Volume1.5 ml Concentration 15 million/ml Progressive motility 32% Normal forms 4%

Exclusion

  • Women with evidence of hyper-or hypothyroidism, hyperprolactinemia, Cushing's syndrome, congenital adrenal hyperplasia or androgen-secreting tumors.
  • Women with factors of infertility other than PCOS
  • Women with incomplete data.

Key Trial Info

Start Date :

July 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2018

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT03316469

Start Date

July 1 2018

End Date

December 1 2018

Last Update

June 27 2018

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS | DecenTrialz